Skip to content
Vivo logo
← All articles

Clinicians: CJC-1295 Raises IGF-I Up to 28 Days, Sermorelin Pulses

Clinicians: CJC-1295 Raises IGF-I Up to 28 Days, Sermorelin Pulses

Abstract illustration of peptide timing patterns

CJC-1295, particularly the DAC form, produces growth hormone and IGF-I elevations that persist for days to weeks, while Sermorelin triggers a short, pulse-like GH release lasting minutes to hours. This difference in duration drives different dosing schedules and monitoring needs. Both peptides are typically available in the United States as compounded prescriptions rather than as FDA-approved drugs, a distinction that matters for anyone evaluating them for clinical or research use.

TL;DR:

  • CJC-1295 with DAC can elevate growth hormone for over six days and IGF-I for up to 28 days after a single dose, requiring less frequent injections.
  • Sermorelin’s short plasma half-life limits its effect to minutes or hours, necessitating more frequent dosing to sustain hormonal activity.
  • Evidence shows CJC-1295 reliably raises GH and IGF-I in controlled trials, but long-term safety data, especially for compounded versions, remains limited.
  • Both peptides are available primarily as compounded prescriptions in the US, with safety monitoring focused on IGF-I levels due to potential risks of sustained growth factor elevation.
  • Combining GHRH analogues like CJC-1295 with Ipamorelin, which acts on a different receptor, can produce larger GH pulses, but clinical outcomes are not well established.
Vivo Clinicvivoclinic.orgExplore Supervised Sermorelin CareVivo Clinic provides personalized, provider-supervised Sermorelin treatment through licensed U.S. pharmacies and secure telehealth care.Visit Vivo Clinic

Table of Contents

How CJC-1295 and Sermorelin compare at a glance

Both peptides stimulate the pituitary to release growth hormone, but they diverge sharply in how long that effect lasts and how often dosing is required.

  • Receptor target: both CJC-1295 and Sermorelin act on the GHRH receptor, while Ipamorelin works through a separate ghrelin receptor pathway (GHS-R1a).
  • Duration: CJC-1295 with DAC maintains elevated GH for about six days or more after a single dose, with IGF-I staying above baseline for up to 28 days after repeated dosing, according to a controlled pharmacokinetic study. Sermorelin’s effect is brief, consistent with its short plasma persistence.
  • Dosing frequency: CJC-1295’s extended activity supports less frequent injections; Sermorelin’s short action generally calls for more frequent dosing to mimic natural GH pulses.
  • Evidence base: CJC-1295 has published pharmacokinetic and pharmacodynamic data from controlled trials; Sermorelin’s evidence draws more heavily on decades of clinical use as a diagnostic and therapeutic GHRH analogue.

Ipamorelin is often discussed alongside both because it reaches a different receptor, and pairing it with a GHRH analogue can amplify the GH pulse without directly affecting the GHRH pathway itself.

Why receptor biology explains the difference in GH release patterns

Sermorelin is a truncated fragment of growth hormone releasing hormone, specifically the amino acids most responsible for activating the pituitary’s GHRH receptor. Once bound, it prompts a natural, short burst of GH release that closely resembles the body’s own pulsatile secretion pattern. Its biological activity ends quickly because the native peptide is cleared from circulation within minutes.

CJC-1295 is a modified GHRH analogue built to resist that rapid clearance. The non-DAC version behaves closer to Sermorelin in timing, but the DAC form includes a drug affinity complex that binds to albumin in the bloodstream, extending the peptide’s presence and converting what would be a brief pulse into a sustained signal. That modification is the reason a single dose of CJC-1295 can elevate GH for days rather than minutes, as shown in dose-dependent trial data.

Ipamorelin takes an entirely different route. It activates GHS-R1a, the ghrelin receptor, which triggers GH release through a signaling pathway separate from the GHRH receptor. Because the two pathways are not redundant, combining a GHRH analogue with a ghrelin receptor agonist can produce a larger GH pulse than either compound alone, without necessarily increasing the off-target effects associated with broader secretagogues. For anyone interpreting a lab panel or designing a monitoring plan, the receptor target determines whether a result reflects a sharp pulse or a slow, tonic rise in IGF-I.

Two receptor pathways converging on GH release

How long GH and IGF-I stay elevated after each peptide

The pharmacokinetic distinction between these two peptides is the clearest practical difference clinicians and researchers encounter. In a controlled study, subcutaneous CJC-1295 produced dose-dependent increases in mean plasma GH of roughly 2 to 10 times baseline for six days or more after a single injection, with mean IGF-I rising 1.5 to 3 times baseline for 9 to 11 days, according to peer-reviewed pharmacokinetic data. The same study estimated CJC-1295’s half-life at 5.8 to 8.1 days, and after repeated dosing, IGF-I remained above baseline for up to 28 days. Findings consistent with sustained stimulation were also reported in The Journal of Clinical Endocrinology & Metabolism.

Sermorelin behaves on a completely different timescale. Its plasma half-life is measured in minutes, and the resulting GH release follows the pulse pattern the pituitary produces naturally, rising and falling within an hour or two of administration rather than persisting for days.

Timeline comparing CJC-1295 and Sermorelin duration

The clinical implication follows directly from these numbers. CJC-1295’s extended half-life means IGF-I can accumulate across repeated doses, so a monitoring plan needs to account for cumulative elevation rather than a single peak. Sermorelin’s short action means more frequent dosing is typically required to maintain any meaningful effect on GH secretion, but it carries less risk of the kind of sustained IGF-I buildup that longer-acting analogues can produce.

What the clinical evidence shows and where it falls short

The strongest published data for CJC-1295 come from a single controlled trial examining single and repeated subcutaneous dosing in healthy adults, which found dose-dependent GH and IGF-I increases without serious adverse reactions at the doses tested, as reported in both the original pharmacokinetic study and the corresponding Journal of Clinical Endocrinology & Metabolism publication. These results establish that the peptide reliably raises GH and IGF-I in a dose-dependent manner, but the trial’s sample size and follow-up duration were limited, and the endpoints measured were hormonal, not direct clinical outcomes like body composition or functional status.

Sermorelin’s evidence base is older and broader in one sense: it has been used clinically and diagnostically as a GHRH analogue for decades, giving providers a longer track record of real-world use. However, much of that experience predates modern trial standards, so direct head-to-head comparisons against CJC-1295 using consistent endpoints are scarce.

For both peptides, GH and IGF-I levels are surrogate markers. They indicate that the intended biological pathway is being activated, but they do not by themselves confirm a specific clinical benefit, which is why controlled, longer-duration studies remain a gap in the evidence for either compound.

Safety signals, monitoring, and the U.S. compounding landscape

Reported adverse effects in CJC-1295 trials have been limited, but the elevated IGF-I levels these peptides are designed to produce carry theoretical risks worth tracking, including the kind of concerns that accompany any sustained growth factor elevation. Monitoring IGF-I at baseline and periodically during treatment is the primary safety check for either peptide.

The regulatory backdrop matters as much as the pharmacology. In the United States, compounded peptides including CJC-1295 are not FDA-approved drugs. The FDA’s compounding guidance outlines the limits compounders operate under through sections 503A and 503B of the FD&C Act, and a 2020 warning letter specifically cited compounding of CJC-1295 as failing to meet 503A conditions when the bulk substance lacks an applicable monograph.

Practical monitoring steps include confirming the compounding pharmacy’s state license and 503A or 503B status, tracing the specific lot dispensed, and scheduling IGF-I checks at baseline and at regular intervals afterward.

Choosing between a pulse-mimicking and a sustained approach

The choice between these peptides usually comes down to the research or clinical objective rather than a universal preference.

  1. Define the goal first. Sermorelin’s short pulse profile suits objectives that call for mimicking natural GH rhythm, while CJC-1295’s sustained IGF-I elevation suits objectives built around maintaining a steady hormonal signal.
  2. Account for Ipamorelin’s separate pathway. Pairing a GHRH analogue with Ipamorelin changes the GH release curve by adding a ghrelin receptor signal that does not overlap with GHRH activity.
  3. Set a monitoring cadence before starting. Baseline IGF-I, a follow-up at two to four weeks, and periodic rechecks afterward give a clear picture of whether levels are rising as expected or accumulating beyond intended ranges, a point echoed in general peptide patient-evaluation guidance.
  4. Document the compounding source. Confirm pharmacy licensing and lot information for every prescription filled.

Pro Tip: Log IGF-I results against the dosing date, not the collection date, since CJC-1295’s multi-day elevation can make a single snapshot misleading without that context.

How Vivo Clinic approaches supervised Sermorelin prescribing

We provide access to compounded Sermorelin through pharmacies under provider supervision. Every treatment plan starts with a telehealth intake so a provider can review a patient’s history before a prescription is approved, and transparent, traceable pharmacy sourcing is used for safety. Patients using our Sermorelin service receive provider follow-up alongside their prescription rather than a one-time order.

A researcher’s take on picking the right peptide

Sermorelin fits work that needs to preserve natural GH pulsing. CJC-1295 fits work built around sustained IGF-I elevation, but its longer half-life demands closer IGF-I monitoring given how little long-term safety data exists. Given the regulatory gaps around compounded peptides, conservative dosing and documented provider oversight should guide any protocol.

— Jack

Start supervised Sermorelin therapy through Vivo Clinic

We combine telehealth intake, compounding pharmacy use, and provider-managed monitoring so patients can access Sermorelin without navigating sourcing and oversight questions alone.

  • Complete a telehealth intake so a licensed provider can review your history and confirm candidacy.
  • Receive your prescription from a licensed U.S. compounding pharmacy, shipped directly to your door.
  • Continue with scheduled provider follow-up and lab monitoring throughout treatment.

Visit our Sermorelin page to begin the intake process.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

What are the names of some common HGH peptides?

Commonly discussed growth hormone secretagogues include Sermorelin, CJC-1295, and Ipamorelin, each acting on a different receptor pathway to stimulate pituitary GH release. Tesamorelin is another GHRH analogue sometimes mentioned alongside these.

Is Sermorelin a peptide?

Yes, Sermorelin is a peptide, specifically a shortened fragment of growth hormone releasing hormone that retains the portion needed to activate the pituitary’s GHRH receptor. It triggers a short, pulse-like release of growth hormone rather than a sustained elevation.

Does Sermorelin boost testosterone?

Sermorelin’s documented action is stimulating growth hormone release through the GHRH receptor, not a direct testosterone pathway. Any downstream hormonal effects would need to be evaluated with a licensed provider based on individual labs and health history.

How effective are CJC-1295 and Ipamorelin together?

Combining a GHRH analogue like CJC-1295 with Ipamorelin can produce a larger GH pulse because the two peptides act on separate receptors, GHRH receptor and GHS-R1a respectively. Published data on this specific combination’s clinical outcomes remain limited, so effectiveness should be assessed case by case with provider oversight.